49 results on '"Grimaldi, Antonio Maria"'
Search Results
2. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
3. Immunotherapy in Melanoma
4. Clinical trials and drug cost savings for Italian health service
5. Therapeutic Targeting of the Bone Pre-metastatic Niche
6. Pancreatic Cancer: Beyond Brca Mutations
7. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
8. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial
9. Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.
10. Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
11. Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression
12. Hepatocarcinoma: from pathogenic mechanisms to target therapy
13. The Ratio of GrzB+ − FoxP3+ over CD3+ T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
14. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
15. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
16. Clinical trials and drug cost savings for Italian Health Service
17. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
18. Medication related jaw osteonecrosis (MRONJ) late onset 3 years after IPILIMUMAB endovenous administration: a possible role of target therapy
19. Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.
20. Nivolumab for the treatment of small cell lung cancer
21. Clinical trials and drug cost savings for Italian health service.
22. Nivolumab for the treatment of small cell lung cancer.
23. SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.
24. Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
25. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
26. Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma
27. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
28. Single versus combination immunotherapy drug treatment in melanoma
29. Electrochemotherapy in melanoma patients: a single institution experience
30. Clinicopathologic features and surgical management of primary umbilical melanoma: a case series
31. Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
32. High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
33. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
34. Serious haematological toxicity during and after ipilimumab treatment: a case series
35. BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.
36. Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.
37. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
38. Do BRAF inhibitors select for populations with different disease progression kinetics?
39. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
40. Lean oncology: a new model for oncologists
41. Hepatocarcinoma: from pathogenic mechanisms to target therapy
42. Determination of the Wake Frequency Contents for a Twin Shaft Gas Turbine Variable Nozzle Guided Vane
43. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-a in advanced malignant melanoma.
44. The Ratio of GrzB + − FoxP3 + over CD3 + T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma.
45. Do BRAF inhibitors select for populations with different disease progression kinetics?
46. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists
47. The Ratio of GrzB + - FoxP3 + over CD3 + T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma.
48. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
49. Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.